Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Antitumor Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway

NCT06287463 is registered in ClinicalTrials.gov with Deciphera Pharmaceuticals, LLC as lead sponsor.

NCT NCT06287463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06287463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Antitumor Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway
Lead sponsor
Deciphera Pharmaceuticals, LLC
Phase
Phase 1
Overall status
Terminated
Start date
May 14, 2024
Completion date
February 13, 2026
Enrollment
29 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, braf gene mutation, castration-resistant prostate cancer (crpc), craf gene mutation, melanoma, nf1 mutation, non-small cell lung cancer, pancreatic ductal adenocarcinoma, raf mutation, ras mutation